Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo

Table 2

Comparing HCC growth treated by NET-1shRNA alone and in combination with sorafenib.

Groups	MHCC97H (cm^3)
NET-1shRNA	1.354 ± 0.042^●★
Sorafenib	1.201 ± 0.152^●★
Combination	0.558 ± 0.018^●
Untreated	3.459 ± 0.121
Empty vector	3.279 ± 0.084

The average tumor size in each group was 1.354 ± 0.042 cm³, 1.201 ± 0.152 cm³, 0.558 ± 0.018 cm³, and 3.459 ± 0.121 cm³, respectively, (^●𝑃<0.05 compared with untreated group. ^★𝑃<0.05 compared with combination group).